Family · Pharmaceutical analytical standards
Rasagiline
An irreversible monoamine oxidase B (MAO-B) inhibitor for Parkinson's disease, developed at the Technion in Haifa, Israel, by Moussa Youdim and John Finberg; approved in Europe in 2005 and in the United States in 2006. This family brings together the active ingredient, metabolites, labelled standards, nitrosamines and other impurities.
Did you know?It all began with selegiline, the molecule of Hungarian scientist Joseph Knoll: Youdim heard of it in 1972 and travelled to Budapest to obtain a sample.
No product matches your search.
Need a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.
